PDX model details
| PDX ID |
330M |
| Host Strain(and Source) |
NSG Source: Monash University |
| Host Strain Immune system Humanized |
NO |
| Host Type |
Testosterone supplemented |
| Graft Site |
Subcutaneous |
Current Generation (* indicates number of generations grown in Castrate host) |
18 |
| Average PDX Generation Time (days +/- SEM) |
90 ± 9 |
| Tumour preparation |
Tumor solid |
| Tumour Characterization Technology |
Histology, IHC, STR profiling, targeted DNA sequencing, RNAseq |
| Tumour confirmed not to be of Mouse/EBV origin |
Yes; negative for CD45 and/or positive for human CK8/18 and/or human mitochondria by IHC |
| Passage QA performed |
Routine QA every 2-3 passages |
| Associated meta data |
| PDX model availability |
Yes (fixed, frozen) |
| Governance restriction for distribution |
Available to investigators with appropriate ethics approvals, approved EOI from MURAL committee, and material transfer agreements |
| Pubmed ID |
34413304 |
| |
|
| Markers |
330M |
| AR |
Y |
| PSA |
Y |
| PSMA |
Y |
| NE |
N |
| ERG |
N |
This heatmap displays the call type of curated CNVs in the presented samples.
This heatmap displays the call type of CNVs in commonly occurred samples.
This table displays curated CNVs
|
PDX ID
|
Gene Symbol
|
CNV Log2
|
CNV Copy
|
CNV Call
|
Experiments name
|
Platform
|
Reference genome
|
| 330M |
AR |
4.355 |
20.468 |
Gain-High
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
SETDB1 |
1.798 |
6.957 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
EZH2 |
0.884 |
3.691 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
MET |
0.840 |
3.581 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
PIK3CA |
0.834 |
3.564 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
PIK3CB |
0.798 |
3.477 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
EZH2 |
0.774 |
3.420 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
BRAF |
0.735 |
3.328 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
PIK3R2 |
0.723 |
3.302 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
PIK3CB |
0.608 |
3.049 |
Gain
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
KEAP1 |
-0.740 |
1.197 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
CDH1 |
-0.795 |
1.153 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
TP53 |
-0.802 |
1.147 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
PALB2 |
-0.806 |
1.144 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
KEAP1 |
-0.975 |
1.017 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
KMT2C |
-1.395 |
0.761 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
| 330M |
CDKN1B |
-1.511 |
0.702 |
Loss
|
MURAL Prostate Cancer PDX collection |
Targeted Twist Panel |
hg19 |
Clinical Information
| Sample Number |
330M |
| Sample Site |
Liver |
| Sample source |
Biopsy |
| Pathology Tumour Diagnosis |
Adenocarcinoma |
| Gleason Score |
None |
| Primary Gleason Score |
None |
| Secondary Gleason Score |
None |
| Tertiary Gleason Score |
None |
| ISUP Grade Group |
|
| Tumour Grade |
|
| D'Amico Risk Classification |
|
| Tumour Volume (in cc) |
0.0 |
| Treatment Prior to Specimen Collection |
ADT, docetaxel, cabazitaxel, abiraterone, enzalutamide |
| |
|
Patient Information
| Patient Number |
330 |
| Sex |
Male |
| Diagnosis |
Prostate Cancer |
| PSA at diagnosis (ng/mL) |
NA |
| Consent to share data |
|
| |
|
This heatmap displays the mutations of curated sequence variants.
Download Plot
This table displays curated sequence variants
|
PDX ID
|
Gene Symbol
|
Total Read Depth
|
Alternate Frequency
|
Consequence
|
Exon
|
GnomAD AF
|
CADD PHRED score
|
ClinVar significance
|
Platform
|
Experiments Name
|
Reference
|
Library Type
|
Instrument Type
|
| 330M |
TP53 |
200 |
0.99 |
Splice acceptor variant |
. |
. |
24.8 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
RB1 |
197 |
0.99 |
Stop gained |
'20/27 |
. |
43 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
MAG |
377 |
0.66 |
Missense variant |
'4/11 |
4.08E-06 |
25.2 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
VPS13B |
316 |
0.6 |
Stop gained |
'20/62 |
. |
39 |
Pathogenic/likely pathogenic
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
RET |
499 |
0.47 |
Missense variant |
'11/20 |
. |
22.9 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
MEN1 |
230 |
0.4 |
Missense variant |
'2/10 |
. |
22.4 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
LTBP4 |
601 |
0.32 |
Missense variant |
'34/34 |
0.0003721 |
27.5 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
MAST4 |
252 |
0.29 |
Splice donor variant |
. |
. |
34 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
| 330M |
XIRP2 |
428 |
0.29 |
Missense variant |
'9/11 |
. |
25.6 |
-
|
Targeted Twist Panel |
MURAL Prostate Cancer PDX collection |
hg19 |
paired |
NextSeq 500 |
No information in Drug dosing Table